The current meta-analysis concluded that serum HE4 is a promising biomarker with a high degree of specificity and acceptable sensitivity for the diagnosis of ovarian cancer (especially epithelial ovarian cancer). This evidence concerns the gene WFDC2 and ovarian carcinoma.